<?xml version="1.0" encoding="UTF-8"?>
<p>The European Medicines Agency (EMA) has issued a statement advising that patients continue treatment with angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs), despite widely circulated reports that the agents could worsen coronavirus disease (
 <xref rid="ref20" ref-type="bibr">20</xref>). 
 <italic>“It is important that patients do not interrupt their treatment with ACE inhibitors or ARBs and there is no need to switch to other medicines”, the agency said today. “There is currently no evidence from clinical or epidemiological studies that establishes a link between ACE inhibitors or ARBs and the worsening of COVID-19”. </italic>
</p>
